Reacción a "Reaction to the EMA recommendation for the use of the Novavax vaccine"

It is very good news to have a new vaccine that has been evaluated by independent expert committees from international organizations, which really do an in-depth study on safety and efficacy. This vaccine uses a technology that is already known and has worked very well in other vaccines. It offers the advantage that it does not need to be kept in such extreme cold conditions as RNA vaccines, which simplifies transport and maintenance.